Boston, MA -- (ReleaseWire) -- 06/12/2014 -- Global Markets Direct's, 'Colorectal Cancer - Pipeline Review, H1 2014', provides an overview of the Colorectal Cancer's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
View Full Report Details and Table of Contents
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Colorectal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Colorectal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
Companies Mentioned in this Report: Amgen Inc., Adherex Technologies Inc., AstraZeneca PLC, Eli Lilly and Company, Viralytics Ltd., GlaxoSmithKline plc, Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc., Dainippon Sumitomo Pharma Co., Ltd., Oxford BioMedica plc, Aposense Ltd., Novartis AG, Aphios Corporation, Astellas Pharma Inc., CK Life Sciences Int'l., (Holdings) Inc., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., Astex Pharmaceuticals, Inc., Taiho Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Limited, Bayer AG, Advaxis, Inc., 4SC AG, EntreMed, Inc., Celldex Therapeutics, Inc., Enzo Biochem, Inc., Immunomedics, Inc., Idera Pharmaceuticals, Inc., MEI Pharma, Inc., Compugen Ltd., Critical Outcome Technologies Inc., CytRx Corporation, Regeneron Pharmaceuticals, Inc., Dendreon Corporation, LG Life Sciences, Ltd., Jiangsu Hengrui Medicine Co., Ltd., Panacea Biotec Limited, CrystalGenomics, Inc., Microbio Co., Ltd., Rexahn Pharmaceuticals, Inc., Morphotek, Inc., Isarna Therapeutics GmbH, Chipscreen Biosciences Ltd, CIMAB S.A., Supratek Pharma Inc., Fusion Antibodies Ltd, Oxford BioTherapeutics Ltd, Multimmune GmbH, Nerviano Medical Sciences S.r.l., Glycotope GmbH, TheRyte Ltd., Celator Pharmaceuticals, Inc., Arisaph Pharmaceuticals, Inc., Cellectis S.A., MacroGenics, Inc., Boston Biomedical, Inc., PLx Pharma Inc., DanDrit Biotech A/S, Merrimack Pharmaceuticals, Inc., Deciphera Pharmaceuticals, LLC, Jennerex Biotherapeutics, Inc., MolMed S.p.A., Etubics Corporation, Xcovery, Inc., Quintessence Biosciences, Inc., WntResearch AB, 3-V Biosciences, Inc., Phenomenome Discoveries, Inc., Interprotein Corporation, Zyngenia, Inc., Recepta Biopharma S.A., ISU ABXIS Co.,Ltd., Pepscan Therapeutics, NuCana BioMed Limited, KAEL-GemVax Co., Ltd., Otsuka Holdings Co., Ltd., XBiotech USA, Inc., Wellstat Biologics Corporation, Regulon Inc., Gradalis Inc., Mabion SA, SentoClone International AB, Sigmoid Pharma Ltd., Intezyne, Inc, Igenica, Inc., Selvita S.A, Eddingpharm, PsiOxus Therapeutics, Ltd., Hanmi Pharmaceuticals, Co. Ltd., Phosplatin Therapeutics, Vaxeal Holding SA, Oncobiologics, Inc., IMPACT Therapeutics, Inc., LivTech, Inc., Avipep Pty Ltd, Tactic Pharma, LLC, Kadmon Corporation, LLC, Targovax AS, Shanghai Henlius Biotech Co., Ltd., AbbVie Inc., Precision Biologics, Inc., ImmunNovative Developments SL, Oncology Research International Limited, AlphaMab Co., Ltd, TARGETOME, Solvotrin Therapeutics Ltd, CCRP Therapeutics GmbH
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Metastatic Colorectal Cancer - Pipeline Review, H1 2014
- Metastatic Breast Cancer - Pipeline Review, H1 2014
- Breast Cancer - Pipeline Review, H1 2014
- Non-Small Cell Lung Cancer - Pipeline Review, H1 2014
- Pancreatic Cancer - Pipeline Review, H1 2014
- Colon Cancer - Pipeline Review, H1 2014
- Gastric Cancer - Pipeline Review, H1 2014
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014
- Small-Cell Lung Cancer - Pipeline Review, H1 2014
- Cervical Cancer - Pipeline Review, H1 2014